Robert Brown, MD
Urogynecology and Reconstructive Pelvic Surgery · Mobile, ALNPI 1932223526
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,311 of the $8,305 with a category attached, or 76.0%. It is spread thinly across 42 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations.
Across 294 payments — averaging $28.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$2K
- Intuitive Surgical$2K
- AbbVie$1K
- Astellas Pharma US Inc$543
- Boston Scientific$481
- Sumitomo Pharma America, Inc.$455
- plus $2K from 36 others
Across 6 payments — averaging $14,894 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Axonics, Inc.$75K
- Boston Scientific$14K
What the payments were for
- Travel & lodging$98212%
- Food & beverage$6,31176%
- Education$1,01112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,694
- Axonics$800
- Axonics r-SNM System$345
- BOTOX$125
- Orilissa$123
How this compares
Too few urogynecology and reconstructive pelvic surgery providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 115 | $93,483 |
| MyrbetriqMirabegron | 91 | $72,785 |
| PremarinEstrogens, Conjugated | 45 | $18,722 |
| Estradiol | 99 | $4,513 |
| Estradiol (Twice Weekly)Estradiol | 16 | $2,082 |
| Estradiol (Once Weekly)Estradiol | 12 | $1,479 |
| Oxybutynin Chloride ErOxybutynin Chloride | 63 | $968 |
| Fluconazole | 100 | $964 |
| Nystatin-TriamcinoloneNystatin/Triamcinolone Acet | 28 | $625 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 31 | $362 |
| ValacyclovirValacyclovir Hcl | 15 | $300 |
| Famciclovir | 12 | $216 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 46 | $113 |
| Tramadol Hcl | 55 | $90 |
| Promethazine Hcl | 19 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $455 | $93,483115 claims |
| Astellas Pharma US IncMyrbetriq | $543 | $72,78591 claims |
| PfizerPremarin | $252 | $18,72245 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Alabamaon file to place this against a meaningful peer group, so we don't.
Other urogynecology and reconstructive pelvic surgery in Mobile
- Charles HanesMobile$28K
- Vincent ScottMobile$10K
- Brent ParnellBirmingham$208K
- Himanshu AggarwalMontgomery$19K
- George FahyBay Minette$14K
- Alison PickeringHomewood$11K
- David EllingtonBirmingham$9K
- Nicole MassieHomewood$8K
- Meagan CramerHomewood$3K
- Gabriela HalderBirmingham$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.